1. Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines
   Ergul Mutlu Altundag et al, 2022, Anti-Cancer Agents in Medicinal Chemistry CrossRef
2. Gex2SGen: Designing Drug-like Molecules from Desired Gene Expression Signatures
   Dibyajyoti Das et al, 2023, Journal of Chemical Information and Modeling CrossRef
3. Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer
   Jingwei Yao et al, 2020, Frontiers in Pharmacology CrossRef
4. Estrogen Receptors and Ubiquitin Proteasome System: Mutual Regulation
   Irina Kondakova et al, 2020, Biomolecules CrossRef
5. Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery
   Sarita Rani et al, 2020, International Journal of Pharmaceutics CrossRef
6. Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability
   Sarah A. Jeffreys et al, 2020, Cells CrossRef
7. Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib
   Sudhakar Rajoria et al, 2019, Pharmaceutical Research CrossRef
8. Positioning of proteasome inhibitors in therapy of solid malignancies
   Margot S. F. Roeten et al, 2018, Cancer Chemotherapy and Pharmacology CrossRef
9. Antiproliferative effects of Bortezomib in endothelial cells transformed by viral G protein-coupled receptor associated to Kaposi's sarcoma
   A Suares et al, 2017, Cellular Signalling CrossRef